Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,006 | -3,442 | -1,827 | -6,923 | -5,367 |
| Depreciation Amortization | 239 | 235 | 171 | 685 | 567 |
| Accounts payable and accrued liabilities | -61 | N/A | 456 | -2,186 | -1,966 |
| Other Working Capital | 1,580 | 1,485 | 922 | -47 | -272 |
| Other Operating Activity | 121 | 38 | -438 | 2,280 | 1,988 |
| Operating Cash Flow | $-3,128 | $-1,684 | $-716 | $-6,190 | $-5,051 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 63 | 63 | N/A | 50 | N/A |
| Debt Issued | 3,100 | 2,475 | 300 | 6,435 | 5,260 |
| Common Stock Issued | 368 | 43 | 43 | 269 | 200 |
| Financing Cash Flow | $3,531 | $2,580 | $343 | $6,754 | $5,460 |
| Exchange Rate Effect | -7 | -4 | -3 | -24 | -25 |
| Beginning Cash Position | 591 | 591 | 591 | 51 | 51 |
| End Cash Position | 987 | 1,483 | 214 | 591 | 435 |
| Net Cash Flow | $396 | $893 | $-377 | $540 | $384 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,128 | -1,684 | -716 | -6,190 | -5,051 |
| Free Cash Flow | -3,128 | -1,684 | -716 | -6,190 | -5,051 |